Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Iron-Chelating Therapy and Friedreich Ataxia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00224640
Recruitment Status : Completed
First Posted : September 23, 2005
Last Update Posted : March 4, 2009
Information provided by:
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Friedreich ataxia, an autosomal recessive condition, ascribed to frataxin gene expansion, has been shown to result from an iron- induced injury to the mitochondrial respiratory chain. Buffering free radicals with short-chain quinones (Idebenone) protects the patients against cardiomyopathy but not CNS involvement. Removing CNS iron should limit the impact of the neurological symptoms of the disease.

Condition or disease Intervention/treatment Phase
Friedreich Ataxia Drug: Iron chelating intervention Phase 1 Phase 2

Detailed Description:

The current clinical trial is a monocentric open phase1-2 trial in the context of rare diseases framework, aimed to the goal of defining the tolerance/efficacy of the treatment.

Inclusion criteria: minimum age: 13 years Follow up in the Dept of Genetics, Hospital Necker-Enfants Malades, Paris, France

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II
Study Start Date : March 2005
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Arm Intervention/treatment
Experimental: 1
Iron chelating intervention
Drug: Iron chelating intervention
Iron chelating intervention

Primary Outcome Measures :
  1. assessment of iron overload at TO and month2 by imagery [ Time Frame: at months :0, 1 ,2 ,4 ,6 ]

Secondary Outcome Measures :
  1. Clinical (monthly) and biological parameter follow- up ( blood count, [ Time Frame: weekly ]
  2. plasma iron, ferritin, transferrin and liver enzymes) [ Time Frame: every months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Minimum age: 13 years
  2. Molecular confirmation of frataxin gene mutation
  3. Iron overload evaluation
  4. Presence of lactate
  5. Echography response to Idebenone treatment
  6. Urinary test of pregnancy for girls
  7. Sexual abstinence for men
  8. Information consent

Exclusion Criteria:

  1. No disturbance of iron metabolism
  2. No response to Idebenone
  3. Friedreich not confirmed
  4. Polynuclear neutrophils <2 x 109/L or hemoglobin < 8g/dL
  5. No participation to other trial
  6. Doubt regarding the compliance of the patient to protocol
  7. Impossibility to undergo X-ray examination or presence of iron material in the backbone
  8. Pregnant women
  9. Absence of social insurance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00224640

Layout table for location information
Necker Hospital
Paris, France, 75015
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Layout table for investigator information
Principal Investigator: Arnold MUNNICH, Pr,MD,PhD Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Amel Ouslimany, Department Clinical Research of Developpement Identifier: NCT00224640    
Other Study ID Numbers: P041201
PCR 05001
First Posted: September 23, 2005    Key Record Dates
Last Update Posted: March 4, 2009
Last Verified: March 2007
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Iron-chelating treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebellar Ataxia
Friedreich Ataxia
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinocerebellar Degenerations
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Iron Chelating Agents
Trace Elements
Growth Substances
Physiological Effects of Drugs
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action